Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 563Triple Negative Breast Neoplasms 99Ovarian Neoplasms 60Colorectal Neoplasms 52Prostatic Neoplasms 48Carcinoma, Non-Small-Cell Lung 46Neoplasms 39Lung Neoplasms 34Neoplasm Metastasis 30Melanoma 30Endometrial Neoplasms 30Stomach Neoplasms 27Uterine Cervical Neoplasms 26Pancreatic Neoplasms 26Squamous Cell Carcinoma of Head and Neck 23Colonic Neoplasms 20Head and Neck Neoplasms 19Carcinoma, Renal Cell 19Esophageal Neoplasms 17Sarcoma 16Advanced Breast Cancer 15Urinary Bladder Neoplasms 13Small Cell Lung Carcinoma 13Liver Neoplasms 11Carcinoma, Transitional Cell 11Kidney Neoplasms 10Carcinoma, Intraductal, Noninfiltrating 10Brain Neoplasms 10Lymphedema 9Breast Carcinoma In Situ 9

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Locally Recurrent Breast Cancer × Breast × 30 days × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡